Brind.

CMS policy is reportedly affecting product adoption for Edwards Lifesciences, with a new CMS NCD policy expected in September.

2 reports, 1 independent Updated Jul 25

Gone quiet Reached 2 outlets in its first 24 hours

Reports: 2
Developments: 1
Repetition: 50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

CMS policy is reportedly affecting product adoption for Edwards Lifesciences, with a new CMS NCD policy expected in September.

Who's involved

What this event is mainly about

Edwards Lifesciences CMS

Keep exploring

The entities involved

Edwards Lifesciences
American medical technology company
- Edwards Lifesciences and InspireMD were compared in a market analysis.Sat 11:51
CMS
International law firm
- The Trump administration has issued mandates through CMS that specifically apply to Medicaid enrollees in the District of Columbia.Sun 20:19
- CMS, Jonathan Kellerman, and Mark Greaney are collaborating on educational technology and quantum computing in Cleveland.Sat 08:30

Related events

CMS policy could expand the eligible patient pool.Jul 27

Coverage

Newest first; wire copies grouped

Jul 24themarketsdaily.comEdwards Lifesciences (NYSE:EW) Releases Earnings Results, Beats Estimates By $0.04 EPS

1 more outlet ran the same wire story

Jul 25tickerreport.com